ISSN 1070-4280, Russian Journal of Organic Chemistry, 2014, Vol. 50, No. 6, pp. 815–821. © Pleiades Publishing, Ltd., 2014. Original Russian Text © K.V. Shcherbakov, Ya.V. Burgart, V.I. Saloutin, 2014, published in Zhurnal Organicheskoi Khimii, 2014, Vol. 50, No. 6, pp. 833–838.

> Dedicated to Full Member of the Russian Academy of Sciences O.N. Chupakhin on his 80th anniversary

Metal Complexes Based on Functionalized 4-Hydroxypolyfluorocoumarins

K. V. Shcherbakov, Ya. V. Burgart, and V. I. Saloutin

Postovskii Institute of Organic Synthesis, Ural Branch, Russian Academy of Sciences, ul. S. Kovalevskoi/Akademicheskaya 22/20, Yekaterinburg, 620990 Russia e-mail: shcherbakov@ios.uran.ru; saloutin@ios.uran.ru

Received April 11, 2014

Abstract—4-Hydroxypolyfluorocoumarins containing an acetyl, 1-aminoethylidene, ethoxycarbonyl, or aminocarbonyl substituent on C^3 form coordination compounds with transition and rare earth metal cations. Some coumarin derivatives and their metal complexes show fluorescent properties.

DOI: 10.1134/S1070428014060104

Coumarin derivatives are widely used in practice. They possess various biological and pharmacological properties [1]; in particular, 4-hydroxycoumarins are used in medicine as indirect anticoagulants [2]. Substituted coumarins display unique photochemical and photophysical properties and are characterized by blue–green luminescence, large Stokes shift, and high fluorescence quantum yield [3]. These properties underlie the applications of coumarins as laser dyes, optical bleaching agents, fluorescent pigments, and sensitizers for phototherapy [4].

Functionalized coumarins are widely used as ligands to obtain metal complexes with different coordination modes. Complexation with coumarins is a promising line in the design of new therapeutic agents [5]. The resulting complexes are superior to free ligands in biological and optical activity [6]. Coumarins containing a 1,3-aminovinyl ketone fragment as substituent are the most attractive ligands for the preparation of biologically active complexes with metals [7].

In the present work we have demonstrated the possibility for synthesizing new coordination compounds on the basis of 3-substituted 4-hydroxypolyfluorocoumarins. We previously developed convenient methods for the preparation of 3-(1-aminoethylidene)-4-oxopolyfluorocoumarins Ia and Ib, 3-acetyl-4hydroxypolyfluorocoumarins IIa and IIb [8], and 3-ethoxycarbonyl-4-hydroxypolyfluorocoumarins IIIa and IIIb [9]. By NMR and IR spectroscopy and X-ray analysis we found that compounds Ia and Ib exist as aminovinvl ketone tautomer with exocyclic double bond and that 3-acetyl- and 3-ethoxycarbonyl-substituted analogs IIa, IIb, IIIa, and IIIb have preferentially enol structure with endocyclic double bond [10]. These structural features determine the ability of compounds I-III to act as complexing ligands.

With a view to extend the series of potential ligands based on 4-hydroxypolyfluorocoumarins, coumarin **IIIb** was treated with benzylamine in boiling toluene (with simultaneous removal of water as azeotrope) to obtain *N*-benzyl-6,7,8-trifluoro-4-hydroxy-2-oxo-2*H*-



Scheme 1.



chromene-3-carboxamide (IV) (Scheme 1). When the reaction was carried out under microwave irradiation, the yield of IV increased from 59 to 85%.

Analogous reaction of coumarin **IIIb** under mild conditions (in ethanol at room temperature) afforded benzylammonium 3-ethoxycarbonyl-6,7,8-trifluoro-2oxo-2*H*-chromen-4-olate which, like other structurally related salts, inhibited hydrogen chloride-induced corrosion of low-carbon steel at a low concentration [11]. Under more severe conditions, the product was amide **IV** rather than that resulting from concurrent nucleophilic substitution of the hydroxy group (unlike transformations of 4-hydroxycoumarin and its fluorinated analog [12]). Preferential formation of carboxamide **IV** is likely to be determined by electronic and steric factors which make the ester group in initial coumarin **IIIb** more accessible to nucleophilic attack.

The structure of **IV** was proved by both spectral methods (see Experimental) and X-ray analysis (see figure). The H² proton in the keto–enol fragment of molecule **IV** is delocalized between the O³ and O⁴ oxygen atoms. The O³–H² and O⁴–H² bond lengths are 1.27(2) and 1.20(2) Å, respectively $[O^3 \cdots O^4 2.430(1) \text{ Å}]$. Nearly symmetric position of H² conforms to leveling of bonds in the keto–enol fragment. The H² atom appears almost on the straight line connecting the O³ and O⁴ atoms, the O³H²O⁴ bond angle being 159(1)°. The second intramolecular hydrogen bond in molecule **IV** involves the N¹ and O² atoms in



Structure of the molecule of *N*-benzyl-6,7,8-trifluoro-4-hydroxy-2-oxo-2*H*-chromene-3-carboxamide (**IV**) according to the X-ray diffraction data. Non-hydrogen atoms are shown as thermal vibration ellipsoids with a probability of 50%.

the carboxamide fragment [$H^1 \cdots O^2$ 2.03(1), $N^1 \cdots O^2$ 2.711(1) Å, $\angle N^1 H^1 O^2$ 132.26°].

4-Hydroxypolyfluorocoumarins Ia, Ib, IIa, IIb, IIIa, and IIIb may be regarded as cyclic analogs of enamino ketones, 1,3-diketones, and 1,3-oxo esters, respectively, which are capable of forming metal complexes with a stable six-membered O,O- or N,Ochelate ring. By treatment of solutions of coumarins Ia, IIa, and IIIb in 50% ethanol with copper(II), nickel(II), cobalt(II), iron(III), and europium(III) salts we obtained the corresponding metal complexes Va, Vb, VIa–VId, VIIa, VIIb, and VIIe (Scheme 2).





VI, R = Me, X = F; VII, R = OEt, X = H; M = Cu^{2+} (a), Ni²⁺ (b), Co²⁺ (c), Fe³⁺ (d), Eu³⁺ (e); Y = OAc, CO₂CF₃, Cl; n = 2, 3.

Complexes V–VII were characterized by the data of elemental analysis and IR spectroscopy, and ¹H and ¹⁹F NMR spectra of the nickel complexes were recorded. The complexes had the composition $M(L-H)_2$ or $M(L-H)_3$ where L is the initial ligand (Ia, IIa, or IIIb). Almost all complexes V–VII were isolated as crystal hydrates. Presumably, the presence of water molecules is necessary for stabilization of the complexes; attempts to remove crystallization water by heating led to their decomposition. The ¹H NMR spectra of nickel chelates Vb, VIb, and VIIb in DMSO-d₆ displayed broadened signals from all groups of protons, which were displaced upfield relative to the



corresponding signals of free ligands I–III. In the IR spectra of V–VII, characteristic absorption bands were also displaced relative to the corresponding bands in the spectra of free ligands; in addition, strong bands in the region $3463-3260 \text{ cm}^{-1}$ were observed due to OH stretching vibrations in water molecules. Unfortunately, we failed to obtain crystals of V–VII suitable for X-ray analysis.

Molecules of carboxamide IV possess two possible coordination sites, enolized 1,3-diketone and carboxamide fragments. The reaction of IV with nickel(II), terbium(III), europium(III), and zinc(II) salts afforded metal complexes VIIIb and VIIIe–VIIIg (Scheme 3). According to the elemental analyses data, coordination of coumarin IV with metal ions involves only one chelating entity, most probably, the diketone fragment. All these complexes, except for nickel complex VIIIb, were isolated as crystal hydrates. When the reactions of **IV** with europium(III) and zinc(II) chlorides were carried out in the presence of 2,2'-bipyridine (bipy), we obtained mixed-ligand complexes **IXe** and **IXg** (Scheme 3) where 2,2'-bipyridine is likely to act as stabilizing ligand. In the IR spectra of **VIII** and **IX**, absorption bands were displaced to lower frequencies as compared to the spectrum of free ligand **IV**. In the ¹H NMR spectra of nickel and zinc complexes **VIIIb**, **VIIIg** and **IXg**, signals from the benzylic protons and 5-H appeared in a stronger field, and the amide proton, in a weaker field, relative to the corresponding signals of ligand **IV**. Compound **IXg** displayed in the ¹H NMR spectrum signals from protons in the bipy and carboxamide ligands with an intensity ratio of 1:1.

Alcoholic solutions of coumarins I and IV at room temperature showed a weak blue fluorescence (see table). In going from ligand IV to zinc complex VIIIg

Compound no.	Electronic absorption spectrum, λ_{max} , nm	Photoluminescence spectrum, λ_{em} , nm	Stokes shift $\Delta\lambda$, nm	Quantum yield ^a
Ι	306, 243	400	94	0.001
IV	310, 293	367	57	0.005
VIIIg	303	389	86	0.020
VIIIe	292, 232	405	113	+ phosphorescence
VIIIf	293, 233	377	84	
IXe	288	387	99	
IXg	305, 294, 233	383	78	0.0022

Absorption and photoluminescence spectra of coumarins I and IV and complexes VIIIe–VIIIg, IXe, and IXg

^a Relative to anthracene ($\Phi = 0.27$).

the emission maximum shifts by 22 nm toward longer wavelengths, and the fluorescence quantum yield increases by a factor of four. Europium(III) and terbium(III) complexes **VIIIe** and **VIIIf** displayed both fluorescence and phosphorescence with the emission maxima in the red and green regions, respectively.

Thus, polyfluorinated 4-hydroxycoumarins functionalized at the 3-position are capable of forming coordination compounds with transition and rare earth metal ions. Coumarin derivatives with nitrogen-containing substituents and their metal complexes exhibit fluorescence properties.

EXPERIMENTAL

The melting points were determined in open capillaries on a Stuart SMP3 melting point apparatus and were not corrected. The IR spectra were recorded in the range from 4000 to 400 cm^{-1} on a Perkin Elmer Spectrum One spectrometer from samples dispersed in mineral oil. The photoluminescence spectra were measured on an Agilent Cary Eclipse instrument from solutions in ethanol at 293 K. The ¹H and ¹⁹F NMR spectra were obtained on a Bruker DRX-400 spectrometer at 400 and 376.4 MHz, respectively, using tetramethylsilane (¹H) and hexafluorobenzene (19 F) as references and DMSO- d_6 as solvent. The mass spectrum (electron impact, 70 eV) of compound IV was recorded on an Agilent GC 7890A/MS 5975C instrument. The elemental compositions were determined on a Perkin Elmer 2400 Series II CHNS-O EA 1108 analyzer. Microwave-assisted syntheses were carried out in a Discover SP microwave reactor module (2455 MHz, 300 W, 0-300 psi). The progress of reactions was monitored by TLC on Sorbfil PTSKh-AF-V-UF plates using chloroform and chloroform-methanol (10:1) as eluents.

The X-ray diffraction data for a single crystal of **IV** were acquired on an Xcalibur 3 diffractometer equipped with a CCD detector (λ Mo K_{α} 0.71073 Å, graphite monochromator, ω -scanning, scan step 1 deg, frame time 20 s). Analytical absorption correction was applied according to the multifaceted crystal model using CrysAlis RED 1.171.29.9 program. The structure was solved by the direct method followed by Fourier syntheses using SHELXS-97 and was refined by the least-squares procedure in full-matrix anisotropic approximation for all non-hydrogen atoms using SHELXL-97 [13].

Initial coumarins **Ia**, **IIa**, and **IIIb** were synthesized according to the procedures described in [8, 9].

N-Benzyl-6,7,8-trifluoro-4-hydroxy-2-oxo-2*H*chromene-3-carboxamide (IV). *a*. A mixture of 0.288 g (1 mmol) of compound IIIb and 0.107 g (1 mmol) of benzylamine in anhydrous toluene was heated under reflux in a flask equipped with a Dean– Stark trap. The progress of the reaction was monitored by TLC, following disappearance of the initial compounds. When the reaction was complete, the solvent was removed, and the solid residue was recrystallized from diethyl ether. Yield 0.206 g (59%), white powder, mp 174°C.

b. A mixture of 0.288 g (1 mmol) of compound IIIb and 0.107 g (1 mmol) of benzylamine in anhydrous toluene was subjected to microwave irradiation in a microwave furnace (100 W, 130°C) over a period of 10 min. The solvent was removed, and the solid residue was recrystallized from diethyl ether. Yield 0.297 g (85%). IR spectrum, v, cm⁻¹: 3278 (CH, NH), 1692 (C=O), 1643 (δNH), 1569, 1486, 1445 (δNH, C=C), 1265, 1226 (C-N), 1027, 999 (C-F). ¹H NMR spectrum, δ , ppm: 4.62 d (2H, CH₂C₆H₅, J = 6.0 Hz), 7.32 m (5H, C_6H_5), 7.87 d.d.d (1H, 5-H, J = 10.0, 8.2, 2.2 Hz), 9.80 t (1H, NH, J = 5.8 Hz). ¹⁹F NMR spectrum, δ_F , ppm: 9.80 m, 13.19 m, 24.04 m (1F each). Mass spectrum, m/z (I_{rel} , %): 349 (14) $[M]^+$, 243 (1) $[M - \text{NHCH}_2\text{C}_6\text{H}_5]^+$, 174 (7) $[\text{C}_7\text{HF}_3\text{O}_2]^+$, 106 (100) $[NHCH_2C_6H_5]^+$, 91 (27) $[CH_2C_6H_5]^+$. Found, %: C 58.49; H 2.77; F 16.39; N 4.17. C₁₇H₁₀F₃NO₄. Calculated, %: C 58.46; H 2.89; F 16.32; N 4.01.

X-Ray diffraction data for compound IV. *M* 349.26; monoclinic crystal system, space group P2(1)/n; unit cell parameters: a = 7.4118(8), b = 7.4493(8), c = 26.175(4) Å; $\beta = 91.341(10)$; V = 1444.8(3) Å³; Z = 4; $d_{calc} = 1.606$ g/cm³; $\mu = 0.140$ mm⁻¹. Total of 3537 reflection intensities were measured at 295(2) K; 1285 independent reflections; R = 0.0323; 238 variables.

Metal complexes V–IX (general procedure). Compound Ia, IIa, IIIb, or IV, 1 mmol, was dissolved in ethanol, a solution of 1 mmol of the corresponding metal salt in water was added, and the mixture was heated under reflux and filtered. The filtrate was cooled, and the precipitate was filtered off and recrystallized from ethanol.

Bis[3-(1-aminoethylidene)-5,6,7,8-tetrafluoro-2-oxo-2H-chromen-4-olato]copper(II) (Va). Yield 0.260 g (85%), gray powder, mp 239°C. IR spectrum, v, cm⁻¹: 3329 (N–H), 1729 (C=O), 1654 (C–N), 1586, 1517 (C=C), 1040, 1017 (C–F). Found, %: C 42.89; H 1.29; F 24.75; N 4.22. C₂₂H₈CuF₈N₂O₆. Calculated, %: C 43.19; H 1.32; F 24.84; N 4.58.

Bis[3-(1-aminoethylidene)-5,6,7,8-tetrafluoro-2oxo-2*H*-chromen-4-olato]nickel(II) dihydrate (Vb). Yield 0.244 g (76%), yellow powder, mp 312°C. IR spectrum, v, cm⁻¹: 3327, 3060 (O–H, N–H), 1717 (C=O), 1651 (C–N), 1577, 1512, 1461 (C=C), 1040, 1015 (C–F). ¹H NMR spectrum, δ, ppm: 2.56 s (3H, CH₃), 10.22 br.s (1H, NH). ¹⁹F NMR spectrum, δ_F, ppm: -2.83 m, 2.08 m, 11.69 m, 16.54 m (1F each). Found, %: C 41.34; H 1.77; F 23.20; N 4.62. C₂₂H₈F₈N₂NiO₆·2H₂O. Calculated, %: C 41.09; H 1.88; F 23.64; N 4.36.

Bis(3-acetyl-5,6,7,8-tetrafluoro-2-oxo-2*H***-chromen-4-olato)copper(II) (VIa).** Yield 0.295 g (96%), blue powder, mp 250°C. IR spectrum, v, cm⁻¹: 1747 (C²=O), 1653, 1630 (C=O), 1575, 1529, 1511 (C=C), 1046, 1014 (C–F). Found, %: C 43.13; H 0.99; F 25.17. $C_{22}H_6CuF_8O_8$. Calculated, %: C 43.05; H 0.99; F 24.76.

Bis(3-acetyl-5,6,7,8-tetrafluoro-2-oxo-2*H***-chromen-4-olato)nickel(II) dihydrate (VIb).** Yield 0.258 g (80%), yellow powder, mp 280°C. IR spectrum, v, cm⁻¹: 3328 (OH), 1696, 1678 (C²=O), 1645, 1630 (C=O), 1602, 1527 (C=C), 1039, 1017 (C–F). ¹H NMR spectrum: δ 2.28 ppm, s (3H, CH₃). ¹⁹F NMR spectrum, δ_F, ppm: –2.16 m, 0.58 m, 10.49 m, 16.28 m (1F each). Found, %: C 40.59; H 1.65; F 23.27. C₂₂H₆F₈NiO₈·2H₂O. Calculated, %: C 40.97; H 1.56; F 23.56.

Bis(3-acetyl-5,6,7,8-tetrafluoro-2-oxo-2*H***-chromen-4-olato)cobalt(II) dihydrate (VIc).** Yield 0.219 g (68%), pink powder, mp 218°C. IR spectrum, v, cm⁻¹: 3460 (O–H), 1702 (C²=O), 1646, 1630 (C=O), 1601, 1525 (C=C), 1038, 1018 (C–F). Found, %: C 40.58; H 1.57; F 23.27. $C_{22}H_6CoF_8O_8 \cdot 2H_2O$. Calculated, %: C 40.95; H 1.56; F 23.56.

Tris(3-acetyl-5,6,7,8-tetrafluoro-2-oxo-2*H***-chromen-4-olato)iron(III) tetrahydrate (VId).** Yield 0.216 g (68%), yellow powder, mp 208°C. IR spectrum, v, cm⁻¹: 3334 (O–H), 1742 (C²=O), 1649, 1628 (C=O), 1502, 1460 (C=C), 1038, 1017 (C–F). Found, %: C 41.21; H 1.65; F 23.54. $C_{33}H_9F_{12}FeO_{12}\cdot4H_2O$. Calculated, %: C 41.58; H 1.80; F 23.91.

Bis(3-ethoxycarbonyl-6,7,8-trifluoro-2-oxo-2*H***-chromen-4-olato)copper(II) (VIIa).** Yield 0.258 g (81%), green powder, mp 345°C. IR spectrum, v, cm⁻¹: 1721 (C²=O), 1646, 1604 (C=O), 1560, 1493, 1435 (C=C), 1078, 1057 (C–F). Found, %: C 45.87; H 1.92; F 17.85. $C_{24}H_{12}CuF_6O_{10}$. Calculated, %: C 45.19; H 1.90; F 17.87.

Bis(3-ethoxycarbonyl-6,7,8-trifluoro-2-oxo-2*H***-chromen-4-olato)nickel(II) dihydrate (VIIb).** Yield 0.271 g (81%), green powder, mp >350°C. IR spectrum, v, cm⁻¹: 3463 (O–H), 1681 (C²=O), 1622 (C=O), 1524, 1485, 1421 (C=C), 1056, 1016 (C–F). ¹H NMR spectrum, δ, ppm: 1.19 br.s (3H, CH₂CH₃), 4.04 br.s (2H, CH₂CH₃), 7.48 br.s (1H, 5-H). ¹⁹F NMR spectrum, δ_F, ppm: 8.58 m, 26.33 m, 34.34 m (1F each). Found, %: C 42.85; H 2.36; F 17.49. C₂₄H₁₂F₆NiO₁₀· 2H₂O. Calculated, %: C 43.08; H 2.41; F 17.04.

Tris(3-ethoxycarbonyl-6,7,8-trifluoro-2-oxo-2*H***-chromen-4-olato)europium(III) dihydrate (VIIe).** Yield 0.240 g (71%), yellow powder, mp 212°C. IR spectrum, v, cm⁻¹: 3396 (O–H), 1708 (C²=O), 1612 (C=O), 1510, 1478, 1424 (C=C), 1054, 985 (C–F). Found, %: C 41.65; H 2.43; F 16.40. C₃₆H₁₈EuF₉O₁₅· 2H₂O. Calculated, %: C 41.20; H 2.11; F 16.29.

Bis(3-benzylcarbamoyl-6,7,8-trifluoro-2-oxo-2*H***-chromen-4-olato)nickel(II) (VIIIb).** Yield 0.283 g (75%), green powder, mp >350°C. IR spectrum, v, cm⁻¹: 3075, 3032 (N–H), 1639 (C²=O), 1596 (C=O), 1553, 1496, 1418 (C=C), 1053, 1016 (C–F). ¹H NMR spectrum, δ, ppm: 3.31 br.s (2H, CH₂C₆H₅), 7.19– 7.89 m (6H, C₆H₅, 5-H). Found, %: C 54.48; H 2.80; F 14.23; N 4.39. C₃₄H₁₈F₆N₂NiO₈. Calculated, %: C 54.07; H 2.40; F 15.09; N 3.71.

Bis(3-benzylcarbamoyl-6,7,8-trifluoro-2-oxo-2*H***-chromen-4-olato)chlorooeuropium(III) tetrahydrate (VIIIe).** Yield 0.283 g (55%), white powder, mp 174°C. IR spectrum, v, cm⁻¹: 3360 (O–H), 3060 (N–H), 1682 (C²=O), 1643 (C=O), 1619, 1569, 1486, 1445 (C=C), 1060, 1017 (C–F). Found, %: C 43.00; H 2.63; Cl 3.97; F 11.53; N 2.78. $C_{34}H_{26}ClEuF_6N_2O_{12}$. 4H₂O. Calculated, %: C 42.72; H 2.74; Cl 3.71; F 11.92; N 2.93.

Acetatobis(3-benzylcarbamoyl-6,7,8-trifluoro-2-oxo-2*H*-chromen-4-olato)terbium(III) dihydrate (VIIIf). Yield 0.204 g (43%), yellow powder, mp >350°C. IR spectrum, v, cm⁻¹: 3293 (O–H), 3068 (N–H), 1686 (C²=O), 1659, 1639 (C=O), 1598, 1559, 1498, 1422 (C=C), 1048, 1011 (C–F). Found, %: C 45.71; H 2.57; F 11.65; N 3.20 $C_{36}H_{21}F_6N_2O_{10}Tb$ · 2H₂O. Calculated, %: C 45.49; H 2.65; F 11.99; N 2.95.

(3-Benzylcarbamoyl-6,7,8-trifluoro-2-oxo-2*H*chromen-4-olato)chlorozinc(II) dihydrate (VIIIg). Yield 0.417 g (86%), white powder, mp 322°C. IR spectrum, v, cm⁻¹: 3344 (O–H), 3074 (N–H), 1652 (C²=O), 1638 (C=O), 1599, 1572, 1504, 1498 (C=C), 1049, 1012 (C–F). ¹H NMR spectrum, δ, ppm: 4.46 d (2H, C**H**₂C₆H₅, J = 5.8 Hz), 7.18–7.26 m (5H, C₆H₅), 7.54 m (1H, 5-H), 10.21 br.s (1H, NH). ¹⁹F NMR spectrum, δ_F, ppm: 8.51 m, 9.13 m, 22.02 m (1F each). Found, %: C 41.88; H 2.59; Cl 7.43; F 11.57; N 3.26. C₁₇H₉ClF₃NO₄Zn · 2H₂O. Calculated, %: C 42.09; H 2.70; Cl 7.31; F 11.75; N 2.89.

Tris(3-benzylcarbamoyl-6,7,8-trifluoro-2-oxo-2*H*-chromen-4-olato)(2,2-bipyridine)europium(III) (IXe). Yield 0.257 g (57%), white powder, mp 238°C. IR spectrum, v, cm⁻¹: 3078 (N–H), 1679 (C²=O), 1592 (C=O), 1559, 1495, 1419 (C=C), 1066, 1007 (C–F). Found, %: C 53.72; H 2.54; F 12.79; N 5.10. $C_{51}H_{27}EuF_9N_5O_{12}$ ·bipy. Calculated, %: C 54.15; H 2.61; F 12.64; N 5.18.

(3-Benzylcarbamoyl-6,7,8-trifluoro-2-oxo-2*H*-chromen-4-olato)(2,2-bipyridine)chlorozinc(II) hydrate (IXg). Yield 0.455 g (73%), white powder, mp 288°C. IR spectrum, v, cm⁻¹: 3259 (O–H), 3106, 3081 (N–H), 1675 (C²=O), 1645 (C=O), 1599, 1552, 1492, 1417 (C=C), 1022, 1010 (C–F). ¹H NMR spectrum, δ , ppm: 4.42 br.s (2H, CH₂C₆H₅), 7.16–7.25 m (5H, C₆H₅), 7.52–8.68 m (9H, C₁₀H₈N₂, 5-H), 10.25 br.s (1H, NH). ¹⁹F NMR spectrum, δ_F , ppm: 8.57 m, 9.23 m, 21.97 m (1F each). Found, %: C 51.84; H 2.72; C1 5.76; F 9.39; N 6.68. C₁₇H₉ClF₃N₃O₄Zn·bipy·H₂O. Calculated, %: C 52.03; H 3.07; Cl 5.69; F 9.14; N 6.74.

This study was performed under financial support by the Presidium of the Ural Branch of the Russian Academy of Sciences (project no. 12-P-3-1020) and by the Program for Support of Young Scientists and Post-Graduate Students of the Ural Branch of the Russian Academy of Sciences (project no. 14-3-NP-344).

The authors thank junior researcher M.S. Valova (Heterocyclic Compounds Laboratory, Institute of Organic Synthesis, Ural Branch, Russian Academy of Sciences) for recording the photoluminescence spectra.

REFERENCES

- Kuznetsova, G.A., *Prirodnye kumariny i furokumariny* (Natural Coumarins and Furocoumarins), Leningrad: Nauka, 1967; Egan, D., O'Kennedy, R., Moran, E., Cox, D., Prosser, E., and Thornes, D., *Drug Met. Rev.*, 1990, vol. 22, no. 5, p. 503; Smyth, T., Ramachandran, V.N., and Smyth, W.F., *Int. J. Antimicrob. Agents*, 2009, vol. 33, no. 5, p. 421.
- Silverman, R.B., J. Am. Chem. Soc., 1981, vol. 103, p. 3910; Mashkovskii, M.D., Lekarstvennye sredstva

(Medicines), Moscow: Novaya Volna, 2002, 14th ed., vol. 1, p. 460.

- 3. Li, J., Li, X., and Wang, Sh., J. Mol. Struct., 2012, vol. 1012, p. 177; Kuznetsova, N.A. and Kaliya, O.L., Russ. Chem. Rev., 1992, vol. 61, no. 7, p. 683; Lin, C.-T., Shin, J.-H., Chen, C.-L., and Yang, D.-Y., Tetrahedron Lett., 2005, vol. 46, p. 5033; Lin, S.-L., Kuo, P.-Y., and Yang, D.-Y., Molecules, 2007, p. 1316; Ghoili, A., Dusek, M., Petricek, V., Ben Aved, T., and Ben Hassen, R., J. Phys. Chem. Solids, 2014, vol. 75, p. 188; Xu, Zh., Ding, G., Zhong, G., Xing, G., Li F., Huang, W., and Tian, H., Res. Chem. Intermed., 2008, vol. 34, nos. 2-3, p. 249; Turki, H., Abid, S., El Gharbi, R., and Fery-Forgues, S., C. R. Chim., 2006, vol. 9, no. 10, p. 1252; Hazra, P. and Sarkar, N., Chem. Phys. Lett., 2001, vol. 342, nos. 3-4, p. 303; da Hora Machado, A.E., de Miranda, J.A., Guilardi, S., Nicodem, D.E., and Severino, D., Spectrochim. Acta, Part A, 2003, vol. 59, no. 2, p. 345.
- Liu, X., Cole, J.M., Waddell, P.G., Lin, T.-C., and McKechnie, S., J. Phys. Chem. C, 2013, vol. 117, p. 14130; He, P., Wang, H., Zhang, L., Wang, J., Jiang, Y., Fan, R., and Chen, D., Opt. Laser Tech., 2012, vol. 44, p. 341; Anufrik, S.S. and Tarkovsky, V.V., J. Appl. Spectrosc., 2010, vol. 77, p. 640.
- Grazul, M. and Budzisz, E., Coord. Chem. Rev., 2009, vol. 253, nos. 21–22, p. 2588; Creaven, B.S., Devereux, M., Karcz, D., Kellett, A., McCann, M., Noble, A., and Walsh, M., J. Inorg. Biochem., 2009, vol. 103, p. 1196; Sathisha, M.P., Shetti, U.N., Revankar, V.K., and Pai, K.S.R., Eur. J. Med. Chem., 2008, vol. 43, p. 2338; Gudasi, K.B., Patil, M.S., and Vadavi, R.S., Eur. J. Med. Chem., 2008, vol. 43, p. 2436; Bagihalli, G.B., Avaji, P.G., Patil, S.A., and Badami, P.S., Eur. J. Med. Chem., 2008, vol. 43, no. 11, p. 2639.
- Hanshaw, R.G., Hilkert, S.M., Jiang, H., and Smith, B.D., *Tetrahedron Lett.*, 2004, vol. 45, p. 8721; Kostova, I. and Nikolova, I., *Am. J. Pharm. Tox.*, 2006, vol. 1, no. 2, p. 30.
- 7. Ketata, I., Mechi, L., Ben Ayed, T., Dusek, M., Petricek, V., and Ben Hassen, R., Open J. Inorg. Chem., 2012, vol. 2, no. 2, p. 33; Manolov, I., Kostova, I., Netzeva, T., Konstantinov, S., and Karaivanova, M., Arch. Pharm., 2000, vol. 333, no. 4, p. 93; Kostova, I., Manolov, I., Netzeva, T., Konstantinov, S., and Karaivanova, M., Eur. J. Med. Chem., 1999, vol. 34, p. 63; Kostova, I., Manolov, I., Netzeva, T., and Karaivanova, M., Arch. Pharm., 2001, vol. 334, no. 5, p. 157; Karaivanova, M., Manolov, I., Ninassyan, M.L., Danchev, N.D., and Samurova, S.M., Pharmazie, 1994, vol. 49, p. 856; Jevtić, V.V., Pešić, M., Radić, G.P., Vuković, N., Sukdolak, S., Klisurić, O., Podolski-Renić, A., Tanić, N., and Trifunović, S.R., J. Mol. Struct., 2013, vol. 1040, p. 216; Rohlíček, J., Ketata, I., Ben Ayed, T., and Ben Hassen, R., J. Mol. Struct., 2013, vol. 1051, p. 280.

- Saloutin, V.I., Skryabina, Z.E., Bazyl', I.T., and Kisil', S.P., *J. Fluorine Chem.*, 1999, vol. 94, no. 1, p. 83; Shcherbakov, K.V., Burgart, Ya.V., and Saloutin, V.I., *Russ. J. Org. Chem.*, 2013, vol. 49, p. 719.
- Bazhin, D.N., Shchegol'kov, E.V., Kudyakova, Yu.S., Shcherbakov, K.V., Burgart, Ya.V., and Saloutin, V.I., *Russ. Chem. Bull., Int. Ed.*, 2011, vol. 60, no. 5, p. 929.
- Shcherbakov, K.V., Burgart, Ya.V., Kodess, M.I., and Saloutin, V.I., *Chem. Heterocycl. Compd.*, 2012, vol. 48, no. 9, p. 1297.
- 11. Shcherbakov, K.V., Gorbunova, T.I., Burgart, Ya.V., and Saloutin, V.I., *Russ. J. Org. Chem.*, 2014, vol. 50, p. 66.
- Badran, M.M., El-Ansari, A.K., and El-Meligie, S., *Rev. Roum. Chim.*, 1990, vol. 35, p. 777; Stoyanov, E.V. and Ivanov, I.C., *Molecules*, 2004, p. 627; Chavan, A.P., *J. Chem. Res., Synop.*, 2006, p. 179; Shcherbakov, K.V., Burgart, Ya.V., and Saloutin, V.I., *Russ. Chem. Bull., Int. Ed.*, 2006, vol. 55, no. 7, p. 1215.
- 13. Sheldrick, G.M., *Acta Crystallogr., Sect. A*, 2008, vol. 64, p. 112.